Results 191 to 200 of about 1,116,502 (236)
Some of the next articles are maybe not open access.
The Antifungal Drug Clotrimazole
Acta Crystallographica Section C Crystal Structure Communications, 1998The structure of the title compound, 1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole, C22H17ClN2, has been determined. The molecular conformation showed a weathercock-type structure and the three phenyl rings are almost perpendicular to the imidazole ring.
H, Song, H S, Shin
openaire +2 more sources
Antifungal drugs on the horizon
Journal of the American Academy of Dermatology, 1994In the past 10 years there has been a major expansion in the development of antifungal drugs, but there are still weaknesses in the range and scope of current antifungal chemotherapy. New developments have included the modification of existing drug molecules to eliminate toxicity and improve activity, for instance, the development of the lipid ...
openaire +2 more sources
Antifungal Drug Resistance in Aspergillus
Journal of Infection, 2000This article overviews the emerging problem of antifungaldrug resistance in Aspergillus. Fluconazole and ketocona-zole (KCZ) are inactive against Aspergillus. Validation oftesting procedures for the detection of itraconazole (ITZ)resistance in Aspergillus fumigatusin 19971,2were furthervalidated with posaconazole (SCH-56592)3,4and voricona-zole (VCZ)5 ...
Moore, C.B. +4 more
openaire +3 more sources
Treatment guidelines from the Medical Letter, 2012
There are a number of antifungal drugs authorised for use in animals, the majority being members of the polyene or azole classes. Of these, only two are permitted for use in food animals, at least in the European Union, natamycin and enilconazole. Griseofulvin is a cyclohexenone derivative which has been used in companion and food animal medicine ...
H P Rang +4 more
+5 more sources
There are a number of antifungal drugs authorised for use in animals, the majority being members of the polyene or azole classes. Of these, only two are permitted for use in food animals, at least in the European Union, natamycin and enilconazole. Griseofulvin is a cyclohexenone derivative which has been used in companion and food animal medicine ...
H P Rang +4 more
+5 more sources
ORAL ANTIFUNGAL DRUG INTERACTIONS
Dermatologic Clinics, 1997The recent approval of itraconazole and terbafine for the treatment of onychomycosis has launched a new era in the therapeutic management of this previously resistant form of dermatomycoses. These agents represent safe and effective treatments. The clinician should, however, become knowledgeable with the potential drug interactions that are discussed ...
H I, Katz, A K, Gupta
openaire +2 more sources
Current Opinion in Microbiology, 1999
There have been many new developments in antifungal therapy in the past few years. Some antifungal drugs have been reformulated to reduce toxicity (e.g. new lipid formulations of polyenes), and new derivatives of drugs have been developed to enhance potencies.
openaire +2 more sources
There have been many new developments in antifungal therapy in the past few years. Some antifungal drugs have been reformulated to reduce toxicity (e.g. new lipid formulations of polyenes), and new derivatives of drugs have been developed to enhance potencies.
openaire +2 more sources
1992
The allylammes constitute a recently developed class of synthetic antimycotics characterized functionally by their action as squalene epoxidase inhibitors.1 Figure 6–1 shows the structures of three representative allylamines. Naftifine, the first of these compounds to be discovered, was first synthesized in 1974,2 and its antifungal properties were ...
N S, Ryder, H, Mieth
openaire +2 more sources
The allylammes constitute a recently developed class of synthetic antimycotics characterized functionally by their action as squalene epoxidase inhibitors.1 Figure 6–1 shows the structures of three representative allylamines. Naftifine, the first of these compounds to be discovered, was first synthesized in 1974,2 and its antifungal properties were ...
N S, Ryder, H, Mieth
openaire +2 more sources
Pediatrics In Review, 2016
1. Lynn Smitherman, MD* 1. *Wayne State University School of Medicine, Detroit, MI. 1. 1. Tay E. Azole Antifungal Agents. Tay E. Pediatr Rev. 2005;26(1):20–21 [OpenUrl][1][FREE Full Text][2] 2. 1. Jura S, 2. Hillenbrand K. Fluconazole. Jura S, Hillenbrand K. Pediatr Rev. 2006;27(4):158–159 [OpenUrl][3]
openaire +2 more sources
1. Lynn Smitherman, MD* 1. *Wayne State University School of Medicine, Detroit, MI. 1. 1. Tay E. Azole Antifungal Agents. Tay E. Pediatr Rev. 2005;26(1):20–21 [OpenUrl][1][FREE Full Text][2] 2. 1. Jura S, 2. Hillenbrand K. Fluconazole. Jura S, Hillenbrand K. Pediatr Rev. 2006;27(4):158–159 [OpenUrl][3]
openaire +2 more sources
Antifungals and antifungal drug discovery.
2012Abstract This chapter discusses: (1) important clinical aspects of invasive clinical mycoses, i.e., candidosis and aspergillosis; (2) current antifungal therapeutic options for invasive mycoses; (3) antifungal drug resistance; and (4) approaches to antifungal drug discovery, including identification of drug targets.
R. Calderone +6 more
openaire +1 more source
The Lancet, 2003
The echinocandins are large lipopeptide molecules that are inhibitors of beta-(1,3)-glucan synthesis, an action that damages fungal cell walls. In vitro and in vivo, the echinocandins are rapidly fungicidal against most Candida spp and fungistatic against Aspergillus spp.
openaire +3 more sources
The echinocandins are large lipopeptide molecules that are inhibitors of beta-(1,3)-glucan synthesis, an action that damages fungal cell walls. In vitro and in vivo, the echinocandins are rapidly fungicidal against most Candida spp and fungistatic against Aspergillus spp.
openaire +3 more sources